Study on the Use of Virtual Reality Neuropsychological Therapy Technology (VRNT) for Chronic Back Pain
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Chronic Pain
- Sponsor
- CognifiSense Inc.
- Enrollment
- 72
- Locations
- 1
- Primary Endpoint
- Change in Pain Intensity and Interference.
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
Participants with chronic back pain will complete an online eligibility questionnaire. After signing a consent form, eligible participants enter a two-week baseline period ("Baseline Period") during which they complete a daily pain survey. Following the Baseline Period all participants complete an MRI scan. After the MRI, scan participants are randomized into a treatment group ("Therapy Group") or a no-intervention group ("Standard of Care Group" or "SOC Group") with a ratio of 1:1 (treatment:SOC). Therapy Group participants receive education about chronic pain. They also participate in sessions to personalize their Virtual Reality (VR) experience, and to complete training on the use of the VR hardware and software. Therapy Group participants complete the treatment for 8 weeks ("Therapy Period"), after which they return the VR equipment. All participants take a second MRI scan approximately 8-weeks after the first MRI; for the Therapy Group this is at the end of the Therapy Period. After the Therapy Period, Therapy Group participants continue to complete daily pain surveys during a two-week follow-up period ("Follow-Up Period"). All participants complete self-reported clinical outcomes and behavioral measures surveys before and after the Baseline Period, 4 weeks after the first MRI (for Therapy Group this is mid-way through the Therapy Period), and before and after the Follow-Up Period. For Therapy Group participants the study ends with the final surveys and an exit interview at the end of the Follow-up Period. Study Extension (Add-on): SOC Group participants may receive the treatment after the Follow-Up period. Those who elect to do so will complete the same set of surveys as the Therapy Group did during the treatment phase; however, since there is no comparison group, data from this study extension is not used in the main outcomes analyses.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Participants aged 21 to 70 with Chronic Back Pain.
- •Chronic Back Pain will be defined according to criteria established by recent NIH task force. Pain duration must be ≥ 3 months, with back pain being an ongoing problem for at least half the days of last 6 months; i.e., either pain every day for past 3 months, or half or more of the days for past 6+ months.
- •Subjects must rate pain intensity at ≥ 4/10 on Brief Pain Inventory (average pain over the last week).
- •Participants must also be comfortable and able to communicate via email, text message, or phone in English. Participants must also be comfortable using a video-conferencing service such as Zoom to complete the on-line sessions.
Exclusion Criteria
- •Applicants, who are pregnant, planning pregnancy, or breastfeeding
- •Back pain associated with compensation / litigation within 1 year.
- •Leg pain greater than back pain (suggests neuropathic pain; may be less responsive to psychological therapy).
- •Chronic pain other than chronic back pain.
- •Diagnoses of schizophrenia, multiple personality dissociative identity disorder.
- •History of major depressive disorder not controlled with medication or other conditions that produce significant cognitive or emotional disability.
- •History of substance abuse.
- •Inability to undergo MRI (determined at screening; see XVI: Risks to Participants).
- •Any clinically significant unstable medical abnormality or acute or chronic disease of cardiovascular, gastrointestinal, respiratory (e.g., chronic obstructive pulmonary disease), hepatic, or renal systems; including: history of cardiovascular disease or issues (e.g., recent heart attack), stroke; brain surgery, or brain tumor; Diabetes; cancer (last 12 months); diagnosis of a specific inflammatory disorder: rheumatoid arthritis, polymyalgia rheumatica, scleroderma, Lupus; polymyositis; or Cauda Equina syndrome.
- •History of seizure disorder, epilepsy, convulsions, or increased intracranial pressure anytime except pediatric febrile seizures.
Outcomes
Primary Outcomes
Change in Pain Intensity and Interference.
Time Frame: Change from pre-treatment to post-treatment = 8 weeks.
Brief Pain Inventory-short form (BPI-SF). Measured on Scale of 0 to 10, 0 = no pain, 10 = worst pain imaginable.
Secondary Outcomes
- Change in Back Pain Disability.(Change from pre-treatment to post-treatment = 8 weeks.)
- Change in Quality of Life.(Baseline (average of survey data at beginning and end of a 2-week baseline period) and at the end of the 8 week therapy / control period.)